BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17244971)

  • 1. Bleeding gums: duloxetine may be the cause.
    Balhara Y; Sagar R; Varghese ST
    J Postgrad Med; 2007; 53(1):44-5. PubMed ID: 17244971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Digging for data on harms in duloxetine trials.
    Doshi P; Zito J; dosReis S
    BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
    [No Abstract]   [Full Text] [Related]  

  • 3. Burning paresthesia related to duloxetine therapy.
    Woo YS; Bahk WM
    J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
    Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
    Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study.
    Maund E; Tendal B; Hróbjartsson A; Lundh A; Gøtzsche PC
    BMJ; 2014 Jun; 348():g3555. PubMed ID: 24899651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine-induced cutaneous adverse reaction.
    Oulis P; Masdrakis VG; Karakatsanis NA; Karapoulios E; Kouzoupis AV; Soldatos CR
    J Clin Psychopharmacol; 2008 Feb; 28(1):104-5. PubMed ID: 18204353
    [No Abstract]   [Full Text] [Related]  

  • 7. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
    Lee SI; Keltner NL
    Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
    [No Abstract]   [Full Text] [Related]  

  • 8. Manic switching in patients receiving duloxetine.
    de Dios C; Ezquiaga E
    Am J Psychiatry; 2007 Jul; 164(7):1121. PubMed ID: 17606669
    [No Abstract]   [Full Text] [Related]  

  • 9. [Duloxetine reduces pain and depression].
    Krankenpfl J; 2004; 42(7-10):246-7. PubMed ID: 15675408
    [No Abstract]   [Full Text] [Related]  

  • 10. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
    Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
    Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate switching from moclobemide to duloxetine may induce serotonin syndrome.
    Jimenez-Genchi A
    J Clin Psychiatry; 2006 Nov; 67(11):1821-2. PubMed ID: 17196070
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
    Brecht S; Kajdasz D; Ball S; Thase ME
    Int Clin Psychopharmacol; 2008 Nov; 23(6):317-24. PubMed ID: 18854719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function.
    Ravindran LN; Eisfeld BS; Kennedy SH
    J Clin Psychopharmacol; 2008 Feb; 28(1):107-8. PubMed ID: 18204355
    [No Abstract]   [Full Text] [Related]  

  • 14. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications.
    Maund E; Tendal B; Hróbjartsson A; Jørgensen KJ; Lundh A; Schroll J; Gøtzsche PC
    BMJ; 2014 Jun; 348():g3510. PubMed ID: 24899650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine in the long-term treatment of major depressive disorder.
    Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
    J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duloxetine--three birds with one stone?
    Michel MC
    Int J Clin Pract; 2007 Aug; 61(8):1247-8. PubMed ID: 17627705
    [No Abstract]   [Full Text] [Related]  

  • 17. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
    Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
    J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive monitoring of duloxetine: results of a web-based intensive monitoring study.
    Härmark L; van Puijenbroek E; van Grootheest K
    Eur J Clin Pharmacol; 2013 Feb; 69(2):209-15. PubMed ID: 22688722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
    Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
    Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
    Seguí J; López-Muñoz F; Alamo C; Camarasa X; García-García P; Pardo A
    J Psychopharmacol; 2010 Aug; 24(8):1201-7. PubMed ID: 19282423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.